Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma

作者：Khalil Farah K^*; Altiok Soner

来源：Cancer Control, 2015, 22(2): 193-199.

DOI：10.1177/107327481502200210

Background: Worldwide, lung cancer is the most common cause of mortality. Toxins from tobacco smoke are known to increase the risk of lung cancer; however, up to 15% of lung cancer-related deaths in men and up to 50% of lung cancer-related deaths in women occur in people who do not smoke. Despite the fact that chemotherapy generally provides a survival benefit for non-small-cell lung cancer, not every patient will respond to therapy and many experience therapy-related adverse events. Thus, predictive markers are used to determine which patients are more likely to respond to a given regimen.
Methods: We reviewed the current medical literature in English relating to predictive markers that may be positive, such as the presence of an activating EGFR mutation.
Results: The advances in using EGFR as a molecular predictive marker were summarized. This biomarker influences therapeutic response in patients with lung adenocarcinoma. Clinical evidence supporting its value is also reviewed.
Conclusions: The use of EGFR as a predictive factor in lung adenocarcinoma may help target therapy to individual tumors to achieve the best likelihood for long-term survival and to avoid adverse events from medications unlikely to be effective.

• 出版日期2015-4